We present a case of a 70 year-old male with B-cell lymphoma of which the first clinical presentation was cardiac infiltration. The patient underwent full chemotherapy with complete tumour regression. Kardiol Pol 2011; 69, 10: 1063-1065.

Download full-text PDF

Source

Publication Analysis

Top Keywords

b-cell lymphoma
8
year-old male
8
lymphoma year-old
4
male patient
4
patient cardiac
4
cardiac tumour
4
tumour case
4
case year-old
4
male b-cell
4
lymphoma clinical
4

Similar Publications

T cell malignancies after CAR T cell therapy in the DESCAR-T registry.

Nat Med

January 2025

Department of Hematology, University Hospital of Rennes, UMR U1236, INSERM, University of Rennes, French Blood Establishment, Rennes, France.

The risk of T cell malignancies after chimeric antigen receptor (CAR) T cell therapy is a concern, although the true incidence remains unclear. Here we analyzed the DESCAR-T registry database, encompassing all pediatric and adult patients with hematologic malignancies who received CAR T cell therapy in France since 1 July 2018. Of the 3,066 patients included (2,536 B cell lymphoma, 162 B cell acute lymphoblastic leukemia (ALL) and 368 multiple myeloma), 1,680 (54.

View Article and Find Full Text PDF

Zandelisib, a selective, potent PI3Kδ inhibitor, demonstrated favourable outcomes in patients with relapsed or refractory follicular lymphoma in a global phase II study. This phase II study evaluated the efficacy and safety of zandelisib for relapsed or refractory follicular lymphoma or marginal zone lymphoma. Sixty-one patients received zandelisib orally at 60 mg daily continuously in the first two 28-day cycles, followed by intermittent dosing on Days 1-7 following each cycle until progressive disease or unacceptable toxicity.

View Article and Find Full Text PDF

Reduced CAR T expansion post infusion is associated with poor survival in patients with large B cell lymphoma after two or more therapies.

Transplant Cell Ther

January 2025

Institute of Haematology, Royal Prince Alfred Hospital, SLHD, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, NSW, Australia.

CD19 directed chimeric antigen receptor (CAR) T-cell therapy is now standard of care for relapsed/refractory large B-cell non-Hodgkin lymphoma. Despite good overall response rates, many patients still experience disease progression and therefore it is important to predict those at risk of relapse following CAR T-cell therapy. We performed a prospective study using a flow cytometric assay at a single treatment centre to assess early CAR T-cell expansion in vivo 6 - 9 days after CAR-T cell infusion.

View Article and Find Full Text PDF

The genus Euphorbia, belonging to the family Euphorbiaceae, represents a significant ethnobotanical heritage due to the diverse bioactive properties exhibited. In this study, the phytochemical composition and biological activities of latex and aerial parts of the water extract of Euphorbia gaillardotii were investigated. Phytochemical analyses were performed using gas chromatography-mass spectrometry and high-performance liquid chromatography techniques and total antioxidants, phenolics, sugars, organic acids, and aroma components were quantitatively determined.

View Article and Find Full Text PDF

Primary hepatic lymphoma (PHL) is a lymphoproliferative disorder confined to the liver, with no evidence of lymphomatous involvement in other organs. Here, we report a case of diffuse large B-cell lymphoma (DLBCL)-type PHL in a patient with a long history of primary biliary cholangitis (PBC) and Sjögren's syndrome (SS). A 78-year-old woman presented with epigastralgia and was found to have a solitary liver tumor by contrast-enhanced computed tomography (CT).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!